RESOLUTE US 12-Month Outcomes:
Very Low Rates Across All Efficacy and Safety Endpoints

Low Rates in All Safety and Efficacy Endpoints


RESOLUTE US Overall Cohort at 12 Months (2.25-4.0 mm diameter)


 

Low Rates Across All RESOLUTE US Cohorts at 12 Months

 

Robust Trial Design That Enrolled a Broad Range of Patients and Lesions

All Patients

1RESOLUTE US 38-mm substudy is still enrolling.

 

Baseline Characteristics:
Broad range of patients with high percentage of challenging lesions

Patient baseline characteristics
Overall Cohort (2.25–4.00-mm diameter)

Patient Characteristics Resolute DES
(n = 1402)
Age (yr) 64.1 ±10.7
Men (%) 68
Diabetes mellitus (%) 34.4
   Insulin dependent (%) 9.6
Prior MI (%) 21.6
Prior PCI (%) 32.7
Prior CABG (%) 8.8
Mean ejection fraction (%) 58.0 ±9.2
Hyperlipidemia (%) 87.7
Hypertension (%) 84.2
Current smokers (%) 20.9
Stable angina (%) 56.1
Unstable angina (%) 41.9
MI (%) 2.1

 

Lesion Characteristics Resolute DES
(nL = 1573)
RVD (mm) 2.59 ±0.47
Minimal lumen diameter (mm) 0.77 ±0.35
Lesion length (mm) 13.06 ±5.88
Lesions treated per patient 1.13 ±0.35
Average DS (%) 70.67 ±11.52
Type B2/C lesion 75.2
Two vessels treated (%) 10.4
≥1 small vessel (RVD ≤2.75 mm) (%) 68.5
≥1 lesion length > 18 mm (%) 20.0
Vessel location  
   LAD (%) 45.9
   LCX (%) 32.2
   RCA (%) 31.2
   LMCA (%) 0.6

 

Clinical Data Overview

RESOLUTE All Comers
24 Month Results Summary

 
 

Email Page

Send a link to this page by email along with your comments.
Please enter the information below.

  1. (required)
  2. (required)
  3. (required)